Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyIndependence Blue Cross ICD-10 Cancer Coding Polic…
    Ask Trek AI about this page
    CurrentIndependence Blue CrossPolicy N/A

    ICD-10 documentation guidance for cancer

    Customize your policy alerts

    Sign up for all independence_blue_cross policy alerts

    Know when independence_blue_cross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for clinical documentation of neoplasms to support accurate ICD-10-CM coding, intended for clinicians and coding professionals working with Independence Blue Cross records.

    Policy Summary
    PayerIndependence Blue Cross
    PolicyICD-10 documentation guidance for cancer
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 20, 2019
    Next Review DateN/A
    Key ActionDocument to the highest specificity and severity, including laterality, and clearly differentiate benign, in-situ, malignant, and uncertain histologic behavior.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Z85category recommended for personal history of malignant neoplasm when no active treatment
    C50.-example code for active breast cancer (requires additional characters)
    2019-03-20effective date of guidance

    Active disease vs History — Coding Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Active disease vs history coding

    Criteria to distinguish active malignant neoplasm from history of malignancy for coding purposes:

    ALL of the following

    • The patient is not receiving active treatment
    • There are no indications of current disease
    • Then assign a code from category Z85 (Personal history of malignant neoplasm).

    Otherwise

    • If the patient is receiving continuing treatment (example: Tamoxifen)
    • Or there is documentation or indication of current disease or recurrence
    • Then document as active malignant neoplasm and assign the appropriate C‑code (example: C50.- for breast cancer; additional characters required).

      Do not use a Z85 history code when active treatment is ongoing; document as active cancer instead.

    ICD-10 Coding Examples

    History codingICD-10
    Z85Personal history of malignant neoplasm (use when no active treatment and no current disease)
    Active malignant neoplasm exampleICD-10
    C50.-Breast cancer (example of active cancer code; additional characters required)

    Documentation & Actionable Guidance for Clinicians

    Documentation Required

    General documentation requirements

    Document to the highest specificity and severity, including laterality when relevant. Clearly differentiate whether the neoplasm is benign, in‑situ, malignant, or of uncertain histologic behavior.

    • Include laterality when applicable.
    • Differentiate benign vs in‑situ vs malignant vs uncertain histologic behavior.
    Documentation Required

    Malignant neoplasm documentation

    For malignant neoplasm, document the primary site and any secondary sites, and include details of current treatments such as chemotherapy, radiation, hormonal therapy, surgery, watchful waiting, or refusal of treatment.

    • Primary site (original site of the cancer).
    • Secondary sites (locations where cancer has spread).
    • Current treatments: chemotherapy, radiation, hormonal therapy, surgery, watchful waiting, or refusal of treatment.
    Billing Rule

    Active vs history coding guidance

    If the neoplasm has been excised or eradicated and the patient is not receiving active treatment and there are no indications of current disease, assign a Z85 (personal history of malignant neoplasm) code; if the patient is receiving ongoing treatment or there is evidence of current disease, document as active malignant neoplasm and use the appropriate C‑codes.

    • Use Z85 when the neoplasm is excised/eradicated, no active treatment is being given, and there are no indications of current disease.
    • If the patient is receiving treatment (example: Tamoxifen) or there is indication of current disease, document as active cancer and report appropriate C‑codes (e.g., C50.- for breast cancer, with required additional characters).

    Neoplasm Type Definitions

    inv-07: Carcinomas — originate from epithelial cells
    DefinitionCarcinomas: Originate from epithelial cells.
    Common sitesOften arise in organs lined by epithelial cells (e.g., skin, breast, lung, colon).
    Clinical noteDocumentation should specify primary site and laterality when applicable to support accurate ICD-10 coding.
    inv-08: Sarcomas — originate from connective tissues
    DefinitionSarcomas: Originate from connective tissues.
    Tissue typesMay arise from bone, cartilage, fat, muscle, or other connective tissues.
    Clinical noteSpecify exact tissue of origin in documentation to enable precise coding.
    inv-09: Leukemias — originate from blood-forming tissues
    DefinitionLeukemias: Originate from blood-forming tissues.
    Clinical implicationDifferentiate active disease from history of malignancy; if not active and no treatment, assign Z85 category for personal history.
    DocumentationRecord current treatment status and any indications of current disease to determine active vs history coding.
    inv-10: Lymphomas — originate from the immune system
    DefinitionLymphomas: Originate from the immune system.
    Clinical implicationIf neoplasm has been excised and no active treatment is ongoing, use Z85 (personal history) rather than an active C-code.
    DocumentationDocument primary and secondary sites and current treatments (chemotherapy, radiation, hormonal therapy, surgery, watchful waiting) to support coding decisions.
    Policy Summary
    PayerIndependence Blue Cross
    PolicyICD-10 documentation guidance for cancer
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 20, 2019
    Next Review DateN/A
    Key ActionDocument to the highest specificity and severity, including laterality, and clearly differentiate benign, in-situ, malignant, and uncertain histologic behavior.
    SourceLink
    On This Page
    Active disease vs History — Coding CriteriaICD-10 Coding ExamplesDocumentation & Actionable Guidance for CliniciansNeoplasm Type Definitions